

Christopher Lee Bartlett, Ph.D.

MANAGING SCIENTIST

CONTACT INFORMATION

ToxStrategies, A BlueRidge Life Sciences Company
Asheville, NC 28801
Office (201) 749-1250
Mobile (336) 693-7001
cbartlett@toxstrategies.com

PROFESSIONAL PROFILE

Dr. Chris Bartlett is a Managing Scientist in ToxStrategies' Health Sciences practice. He has over 20 years of experience conducting risk assessments and providing strategic regulatory toxicology consulting support. His background assessing materials and finished consumer products spans biotechnology, consumer product companies, and government agencies. Dr. Bartlett's expertise covers all aspects of product stewardship, from assessing chemicals and formulations, hazard and safety labelling, maintaining guidelines, and setting strategies for testing protocols. He is committed to making safer products possible by creating tools and processes to incorporate novel new approach methodologies (NAMs) and next generation risk assessment (NGRA) approaches to drive effective toxicological reviews. In roles supporting government agencies, leading brands, and non-governmental organizations, Dr. Bartlett has helped navigate the space between toxicology and policy to improve product safety and adjust review processes to unlock new efficiencies.

Dr. Bartlett's skills include leading multidisciplinary scientific teams to address emerging health and safety issues. As an experienced program and project manager, Dr. Bartlett has conducted systematic literature reviews involving analyzing and interpreting complex scientific data to evaluate health effects and data gaps in public health investigations. He has also led the safety review of innovative and complex materials to find potentially safer alternative chemicals.

Before joining ToxStrategies, Dr. Bartlett served as a principal toxicology consultant at several private firms, where he provided subject matter expert support to multiple government agencies, including the United States (US) Food and Drug Administration (FDA). He has aided drug submission review, spearheaded cosmetic product safety programs, helped develop a chemical hazard repository software platform for identifying safer alternatives, and prepared and defended safety dossiers for product registration with various international regulatory agencies.

EDUCATION AND DEGREES EARNED

2005 Ph.D., Toxicology, University of North Carolina, Chapel Hill, NC
1999 B.S., Biological Sciences, Carnegie Mellon University, Pittsburgh, PA

PROFESSIONAL ASSOCIATIONS

Society of Toxicology (SOT)
--Sustainable Chemicals through Contemporary Toxicology Specialty Section (SCCT)
Society of Environmental Toxicology and Applied Chemistry (SETAC)
--Advancement and Application of Alternatives Assessments (A4) SETAC Interest Group

SELECTED PROFESSIONAL EXPERIENCE

Consumer Product Safety

Led and implemented raw ingredient and final formulation safety assessment strategy for beauty and personal care products.

Served as study director for safety and clinical studies of beauty and personal care products.

Prepared and defended safety dossiers of cosmetic products for international regulatory agencies.

Prepared claims substantiation dossiers for beauty and personal care products.

Assigned warnings, reviewed use instructions, and approved claims for beauty and personal care products.

Managed the safety and efficacy of insect repellent product reviews, including monitoring studies and submitting applications to EPA.

Developed environmental risk assessment for beauty brands.

Managed alternate source material review programs for beauty and personal care brands.

Provided support to beauty and personal care brands through safety evaluation process reviews and onboarding new staff.

Prepared and submitted clinical trial and regulatory submissions for biotech firms.

Provided guidance on emerging regulatory trends to beauty and personal care companies and supported investigations of safer alternatives through alternative assessments.

Risk Assessment

Conducted risk assessments of consumer product ingredients.

Conducted systematic literature reviews and authored risk assessments for federal clients, including US Environmental Protection Agency (EPA) Provisional Peer-Reviewed Toxicity Values (PPRTVs).

Supported the creation of a hazard assessment repository and associated assessment guidances as a foundational tool for alternatives assessments.

Developed approaches for read-across and ways to utilize NAMS to fill hazard assessment data gaps.

Public Health

Supported creation of a tool to aid in visualizing electronic drug submissions to the FDA to make the review process more dynamic.

Trained FDA pharm/tox reviewers on using electronic tools (Janus/SEW) to more efficiently review drug applications.

Supported creation of the National Toxic Substance Incident Program at the Agency for Toxic Substances and Disease Registry (ATSDR) to provide guidance to first responders in chemical disasters.

Supported creation of an automated tool to evaluate bias in biologic trials at FDA.

Supported FDA Center for Tobacco Products (CTP) with extensive literature reviews on harmful and potentially harmful constituents (HPHC) ingredients in tobacco products.

Supported FDA CTP in evaluating the impact of flavors in tobacco products on consumer behaviors.

Created a public health agenda for psoriasis and psoriatic arthritis.

PEER-REVIEWED PUBLICATIONS

Labib R, Amin R, **Bartlett C**, Hoffman L. 2024. Utilizing integrated testing strategy (ITSv1) defined approach and read across to predict skin sensitization of cannabidiol. *Computation Toxicol* 29(March):100297; doi: [10.1016/j.comtox.2023.100297](https://doi.org/10.1016/j.comtox.2023.100297).

Hoffman AC, Valdes Salgado R, Dresler C, Faller RW, **Bartlett C**. 2016. Flavour preferences in youth vs. adults: A review. *Tob Control* 25(Sup 2):ii32-ii39. doi: [10.1136/tobaccocontrol-2016-053192](https://doi.org/10.1136/tobaccocontrol-2016-053192). PMID: 27633764.

Proctor DM, Suh M, Mittal L, Hirsch S, Valdes Salgado R, **Bartlett C**, Van Landingham C, Rohr A, Crump K. 2016. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. *J Expo Sci Environ Epidemiol* 26(2):224-31; doi: [10.1038/jes.2015.77](https://doi.org/10.1038/jes.2015.77). PMID: 26669850.

Helmick CG, Lee-Han H, Hirsch SC, Baird TL, **Bartlett CL**. 2014. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. *Am J Prev Med* 47(1):37-45; doi: [10.1016/j.amepre.2014.02.012](https://doi.org/10.1016/j.amepre.2014.02.012). PMID: 224746373.

Helmick CG, Sacks JJ, Gelfand JM, Bebo B, Lee-Han H, Baird T, **Bartlett C**. 2013. Psoriasis and psoriatic arthritis: A public health agenda. *Am J Prev Med* 44(4):424-26; doi: [10.1016/j.amepre.2013.01.004](https://doi.org/10.1016/j.amepre.2013.01.004). PMID: 23498110.

Bartlett C, Orvis TJ, Rosson GS, Weissman BE. 2011. BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell cycle arrest. *J Cell Physiol* 226(8):1989-97; doi: [10.1002/jcp.22533](https://doi.org/10.1002/jcp.22533). PMID: 21520050.

Banine F, **Bartlett C**, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS. 2005. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. *Cancer Res* 65(9):3542-7; doi: [10.1158/0008-5472.CAN-04-3554](https://doi.org/10.1158/0008-5472.CAN-04-3554). PMID: 15867346.

Rosson GB, **Bartlett C**, Reed W, Weissmann BE. 2005. BRG-1 and BRM loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton. *J Cell Physiol* 205(2):286-94; doi: [10.1002/jcp.20397](https://doi.org/10.1002/jcp.20397). PMID: 15887247.

Hummer BT, **Bartlett C**, Henry E, Weissman BE. 2003. Expression of Smad4 in the FaDu cell line partially restores TGF-beta growth inhibition but is not sufficient to regulate fibronectin expression or suppress tumorigenicity. *J Cell Physiol* 194(3):289-302; doi: [10.1002/jcp.10202](https://doi.org/10.1002/jcp.10202). PMID: 12548549.

PRESENTATIONS AND ABSTRACTS

Bartlett C, Rigutto G, Whittaker M (*Session Chairs*). Use of chemical hazard assessments to drive informed substitution in alternative assessments. SETAC North America 46th Annual Meeting, Portland, OR, November 2025.

Bartlett C, Rigutto G. Use of NAMs to fill data gaps in support of populating a centralized repository of chemical hazard assessments for alternative assessments. Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Bartlett C, Heine L. Broadening the use of read-across to guide the selection of safer chemical ingredients. Toxicology and Risk Assessment Conference, Dayton, OH, April 2023.

Bartlett C, Heine L. Data sharing as a strategy to accelerate sustainable design. Fire Retardants in Plastics Conference, Philadelphia, PA, April 2023.

Bartlett C, Heine L. Safer chemicals in products and processes. ChemWatch Chemicals Management for Electronics, Virtual, December 2022.

Bartlett C, Heine L. The ChemFORWARD SAFER Program and safer trade name ingredients. SETAC North America 43rd Annual Meeting, Pittsburgh, PA, November 2022.

Bartlett C, Heine L. Stay ahead of regulations and trends. ChemWatch Cosmetic Regulatory Summit, Washington, DC, October 2022.

Bartlett C, Heine L. Full chemical hazard assessments to choose safer alternatives. 26th Annual Green Chemistry & Engineering Conference, Reston, VA, June 2022.

Bartlett C, Heine L. Broadening the use of read-across to guide the selection of safer chemical ingredients. Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Bartlett C, Hoffman L, Labib R. An approach to data mining environmental data for personal care products. OpenTox Conference, Virtual, September 2021.

Anderson J, **Bartlett C**, Feldmann J, Gross V, Mankin A, Lu Q, Matto K, Rosario L. An update on CDISC-SEND data submissions to FDA. Paper SA08, PHUSE US Connect 2020, Orlando, FL, March 2020.

Bartlett C, Spero N, Polywoda V, Pechko A, Labib R, Gilberti E, Gettings S. Efficacy of picaridin-containing insect repellent spray products against West Nile virus vector mosquitoes. Abstract # P-34, 76th Annual AMCA Meeting, Lexington, KY, March 2010.

Bartlett C, Rosson G, Weissman BE. Loss of BRG1 and lung cancer pathogenesis. Abstract #1791, Society of Toxicology 44th Meeting, New Orleans, LA, March 2005.

Bartlett C, Rosson G, Weissman BE. The biological significance of BRG1 mutations found in human cancer cell lines. Abstract #4221, 95th Annual AACR Meeting, Orlando, FL, March 2004.

Bartlett C, Rosson G, Sherman L, Knudsen E, Weissman BE. Reexpression of BRG-1 in deficient cell lines restores expression of genes that block cancer progression. Abstract #3165, 94th Annual AACR Meeting, Washington, DC, July 2003.

Bartlett C, Aul D, Blough MS, D'Andrea M, Hauck J, Kennedy AL, Minkley EG, Brown WE. Monitoring degradation of polyurethane flexible foam in a landfill simulator. Abstract #1230, Society of Toxicology 38th Annual Meeting, New Orleans, LA, March 1999.